Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Gentry

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Toxicology and Environmental Health|December 16, 1997
Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessmentH J Clewell, P R Gentry, J M Gearhart
Toxicology in Vitro : an International Journal Published in Association with BIBRA|June 18, 2014
Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenicP R Gentry, J W Yager, R A Clewell, et al.
Environmental Health Perspectives|May 12, 2000
Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessmentH J Clewell, P R Gentry, T R Covington, et al.
Regulatory Toxicology and Pharmacology : RTP|June 8, 2002
Genetic polymorphisms in assessing interindividual variability in delivered doseL T Haber, A Maier, P R Gentry, et al.
Frontiers in Pharmacology|September 4, 2023
Using available <i>in vitro</i> metabolite identification and time course kinetics for β-chloroprene and its metabolite, (1-chloroethenyl) oxirane, to include reactive oxidative metabolites and glutathione depletion in a PBPK model for β-chloropreneJ L Campbell, H J Clewell, C Van Landingham, et al.
The Science of the Total Environment|July 17, 2001
Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK modelH J Clewell, P R Gentry, J M Gearhart, et al.
Chemosphere|July 1, 1995
Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethyleneH J Clewell, P R Gentry, J M Gearhart, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 25, 2001
Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetoneH J Clewell, P R Gentry, J M Gearhart, et al.
Toxicology and Industrial Health|January 5, 2002
Determination of a site-specific reference dose for methylmercury for fish-eating populationsA M Shipp, P R Gentry, G Lawrence, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 29, 2011
Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeksH J Clewell, R S Thomas, E M Kenyon, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Toxicology and Environmental Health|December 16, 1997
Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessmentH J Clewell, P R Gentry, J M Gearhart
Toxicology in Vitro : an International Journal Published in Association with BIBRA|June 18, 2014
Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenicP R Gentry, J W Yager, R A Clewell, et al.
Environmental Health Perspectives|May 12, 2000
Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessmentH J Clewell, P R Gentry, T R Covington, et al.
Regulatory Toxicology and Pharmacology : RTP|June 8, 2002
Genetic polymorphisms in assessing interindividual variability in delivered doseL T Haber, A Maier, P R Gentry, et al.
Frontiers in Pharmacology|September 4, 2023
Using available <i>in vitro</i> metabolite identification and time course kinetics for β-chloroprene and its metabolite, (1-chloroethenyl) oxirane, to include reactive oxidative metabolites and glutathione depletion in a PBPK model for β-chloropreneJ L Campbell, H J Clewell, C Van Landingham, et al.
The Science of the Total Environment|July 17, 2001
Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK modelH J Clewell, P R Gentry, J M Gearhart, et al.
Chemosphere|July 1, 1995
Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethyleneH J Clewell, P R Gentry, J M Gearhart, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 25, 2001
Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetoneH J Clewell, P R Gentry, J M Gearhart, et al.
Toxicology and Industrial Health|January 5, 2002
Determination of a site-specific reference dose for methylmercury for fish-eating populationsA M Shipp, P R Gentry, G Lawrence, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 29, 2011
Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeksH J Clewell, R S Thomas, E M Kenyon, et al.
Pageof 2